Table 3 Geometric mean concentrations of pertussis antibodies in infants’ blood at ages two and 5 months
Study design | Intervention/ exposure type, mean gestational week at vaccination (range) | Com-parator | Infant blood at 2 months of age (before primary vaccination) | Infant blood at 5 months of age (after primary vaccination | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n: Vaccine /control | Vaccine Geometric mean (95% CI) | Control Geometric mean (95% CI) | Ratio of geometric means (95% CI) | p | n: Vaccine /control | Vaccine Geometric mean (95% CI) | Control Geometric mean (95% CI) | Ratio of geometric means (95% CI) | p | ||||
PT (EU or IU/ml)* | |||||||||||||
Hoang [30] | RCT | Tdap 26 (19–35) | TT | 45/35 | 4.2 (2.9–5.9) | 0.8 (0.5–1.3) | 5.3 (3.0–9.3) | <0.001 | 35/35 | 70 (58–84) | 67 (53–84) | 1.0 (0.8–1.4) | 0.76 |
Hardy-Fairbanks [33] | PCS | Tdap -- (anytime) | no vac. | 11/38 | 15.4 (−-) | 4.8 (−-) | 3.2 (−-) | 15/32 | 56.8 (−-) | 75.2 (−-) | 0.8 (−-) | – | |
Maertens [29] | PCS | Tdap 29 (22–33) | no vac. | 51/26 | 15.5 (12.1–20) | 1.1 (0.7–1.6) | 14.1 (9.0–22.1) | <0.001 | 49/21 | 29 (25–35) | 54 (42–69) | 0.5 (0.4–0.7) | <0.001 |
Ladhani [35] | RCS | TdaP/IPV -- (−-) | no vac. | 129/203 | 28.8 (25.7–32.4) | 43.2 (39.4–47.2) | 0.7 (0.6–0.8) | <0.001 | |||||
FHA (EU or IU /ml) | |||||||||||||
Hoang [30] | RCT | Tdap 26 (19–35) | TT | 45/35 | 59 (48–73) | 23.1 (19.7–27) | 2.6 (1.9–3.4) | <0.001 | 35/35 | 77 (66–90) | 66.6 (56–78) | 1.2 (0.9–1.4) | 0.20 |
Hardy-Fairbanks [33] | PCS | Tdap -- (anytime) | no vac. | 11/38 | 41.6 (−-) | 5.6 (−-) | 7.4 (−-) | – | 15/32 | 61.4 (−-) | 83.6 (−-) | 0.7 (−-) | – |
Maertens [29] | PCS | Tdap 29 (22–33) | no vac. | 51/26 | 121 (100–145) | 23 (19–27) | 5.3 (4.0–7.0) | <0.001 | 49/21 | 65 (56–75) | 54 (41–70) | 1.2 (0.9–1.6) | 0.19 |
Ladhani [35] | RCS | TdaP/IPV -- (−-) | no vac. | 131/199 | 25.5 (23.0–28.3) | 41.1 (37.5–45.1) | 0.4 (0.2–0.6) | <0.001 | |||||
PRN (EU or IU /ml) | |||||||||||||
Hoang [30] | RCT | Tdap 26 (19–35) | TT | 45/35 | 46 (32–66) | 7.8 (6.6–9.4) | 5.9 (3.8–9.1) | <0.001 | 35/35 | 83 (65–104) | 132.6 (104–168) | 0.6 (0.5–0.9) | 0.006 |
Hardy-Fairbanks [33] | PCS | Tdap -- (anytime) | no vac. | 11/38 | 32.1 (−-) | 3.9 (−-) | 8.2 (−-) | – | 15/32 | 34.1 (−-) | 50.7 (−-) | 0.7 (−-) | – |
Maertens [29] | PCS | Tdap 29 (22–33) | no vac. | 51/26 | 253 (183–351) | 17 (14.5–21) | 14.9 (9.3–23.8) | <0.001 | 49/21 | 68 (56–84) | 87 (62–121) | 1.2 (0.9–23.8) | 0.19 |
FIM (EU or IU /ml) | |||||||||||||
Hardy-Fairbanks [33] | PCS | Tdap -- (anytime) | no vac. | 11/38 | 296.4 (−-) | 13.0 (−-) | 22.8 (−-) | – | 15/32 | 15.0 (−-) | 10.0 (−-) | 1.5 (−-) | – |
Ladhani [35] | RCS | TdaP/IPV -- (−-) | no vac. | 130/197 | 113.9 (99.0–131.1) | 224.9 (196.1–258.0) | 0.5 (0.2–1,3) | 0.16 | |||||